Recently, adjuvant therapy with abemaciclib in combination with endocrine therapy was approved by the Food and Drugs Administration (FDA) in the USA as a treatment option in high-risk, hormone receptor positive, HER2 negative, node-positive, early breast cancers with Ki-67 ≥ 20% [36]. This evidence concerns the gene NR4A1 and breast cancer.